Company: PACB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001299130-25-000156
Chunk: 8

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
 comprehensive income267 422 Accumulated deficit (2,616,931)(2,148,926)Total stockholders’ equity 61,489 506,594 Total liabilities and stockholders’ equity $825,470 $1,260,447 

See accompanying notes to the condensed consolidated financial statements.

Q2 Fiscal 2025 Form 10-Q3

Table of Contents

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)

Three Months Ended June 30,Six Months Ended June 30,(In thousands, except per share amounts)2025202420252024Revenue:Product revenue $33,083 $31,746 $64,196 $66,755 Service and other revenue 6,683 4,267 12,723 8,068 Total revenue 39,766 36,013 76,919 74,823 Cost of Revenue:Cost of product revenue 20,022 23,083 46,355 45,530 Cost of service and other revenue 4,853 3,366 8,631 7,104 Amortization of acquired intangible assets183 2,628 4,528 3,971 Loss on purchase commitment24 998 4,092 998 Total cost of revenue 25,082 30,075 63,606 57,603 Gross profit14,684 5,938 13,313 17,220 Operating Expense:Research and development 22,529 38,485 51,582 81,940 Sales, general and administrative 36,175 45,877 76,343 89,630 Impairment charges— 93,200 15,000 93,200 Amortization of acquired intangible assets833 4,222 362,875 9,728 Change in fair value of contingent consideration— — (18,700)(70)Total operating expense 59,537 181,784 487,100 274,428 Operating loss (44,853)(175,846)(473,787)(257,208)Interest expense (1,738)(3,542)(3,475)(7,117)Other income, net 4,696 6,069 8,990